Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal...

25
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

TAGS:

Transcript of Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal...

Page 1: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 2: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Disclosure

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 3: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Slide 3

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 4: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

ICON7/AGO-OVAR 11

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 5: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

ICON7/AGO-OVAR 11 <br />PFS and OS

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 6: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

ICON7/AGO-OVAR 11 <br />PFS and OS<br />High risk group suboptimal stage III and stage IV

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 7: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Molecular Classification of HGS Ovarian Cancer

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 8: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Slide 8

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 9: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Slide 9

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 10: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Slide 10

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 11: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Slide 11

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 12: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Slide 12

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 13: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Overall (n=359)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 14: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />High risk for progression (n=119)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 15: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Proliferative Subtype (n=96)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 16: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Mesenchymal Subtype (n=68)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 17: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Differentiated Subtype (n=73)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 18: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Immunoreactive Subtype (n=122)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 19: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Slide 19

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 20: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Proliferative Subtype HGS (n=63)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 21: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Mesenchymal Subtype HGS (n=43)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 22: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Summary

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 23: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Conclusion

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 24: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Acknowledgements

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 25: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Summary

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting


Bevacizumab prevents brain metastases formation in lung … · 2016-01-23 · Ilhan-Mutlu et al Bevacizumab prevents brain metastases 1 Bevacizumab prevents brain metastases formation

Bevacizumab prevents brain metastases formation in lung … · 2016-01-23 · Ilhan-Mutlu et al Bevacizumab prevents brain metastases 1 Bevacizumab prevents brain metastases formation

Concepts Concepts thérapeutiquesthérapeutiques du du ... · Cisplatin 75mg/m2 Bevacizumab 15 mg/kg q21d 4 cycles Docetaxel 75mg/m2 Bevacizumab 2 weeks 15 mg/kg Surgery Adj. Bevacizumab

Concepts Concepts thérapeutiquesthérapeutiques du du ... · Cisplatin 75mg/m2 Bevacizumab 15 mg/kg q21d 4 cycles Docetaxel 75mg/m2 Bevacizumab 2 weeks 15 mg/kg Surgery Adj. Bevacizumab

Subtype Mapping

Subtype Mapping

Chemotherapy plus or minus bevacizumab for platinum ......Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing

Chemotherapy plus or minus bevacizumab for platinum ......Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing

HEMATOLOCICAL CLONAL DISORDERS (MALIGNANCIES) LYMPHO- PROLIFERATIVE DISORDERS MYELOID DISORDERS MYELO- APLASTIC (?) MYELO- DISPLASTIC MYELO- PROLIFERATIVE.

HEMATOLOCICAL CLONAL DISORDERS (MALIGNANCIES) LYMPHO- PROLIFERATIVE DISORDERS MYELOID DISORDERS MYELO- APLASTIC (?) MYELO- DISPLASTIC MYELO- PROLIFERATIVE.

MFOLFOX-bevacizumab or XELOX- bevacizumab then bevacizumab alone or with erlotinib in 1st line treatment of patients with metastatic colorectal cancer.

MFOLFOX-bevacizumab or XELOX- bevacizumab then bevacizumab alone or with erlotinib in 1st line treatment of patients with metastatic colorectal cancer.

Reconstruction of Highly Proliferative Auto-Tissue ... · Reconstruction of Highly Proliferative Auto-Tissue-Engineered ... (CFE), and the methyl- ... Reconstruction of Highly Proliferative

Reconstruction of Highly Proliferative Auto-Tissue ... · Reconstruction of Highly Proliferative Auto-Tissue-Engineered ... (CFE), and the methyl- ... Reconstruction of Highly Proliferative

RETINAL PIGMENT EPITHELIAL TEARS AFTER INTRAVITREAL BEVACIZUMAB ...retinahi.com/.../11RPE-tears-after-intravitreal-bevacizumab-injection.pdf · AFTER INTRAVITREAL BEVACIZUMAB INJECTION

RETINAL PIGMENT EPITHELIAL TEARS AFTER INTRAVITREAL BEVACIZUMAB ...retinahi.com/.../11RPE-tears-after-intravitreal-bevacizumab-injection.pdf · AFTER INTRAVITREAL BEVACIZUMAB INJECTION

Intravitreal Bevacizumab to Treat Iris Neovascularization ...€¦ · of neovascular glaucoma (NVG) are serious complications for patients with proliferative diabetic retinopathy

Intravitreal Bevacizumab to Treat Iris Neovascularization ...€¦ · of neovascular glaucoma (NVG) are serious complications for patients with proliferative diabetic retinopathy

Presentación de PowerPoint · RESPUESTA INMUNE: Anticuerpos neutralizantes IC 50 (μg/ml)* VSV** NL4-3a AC10 aVI 191 92BR025 aCM244 92UG024a Subtype B Subtype B Subtype A Subtype

Presentación de PowerPoint · RESPUESTA INMUNE: Anticuerpos neutralizantes IC 50 (μg/ml)* VSV** NL4-3a AC10 aVI 191 92BR025 aCM244 92UG024a Subtype B Subtype B Subtype A Subtype

Prepared by Kurt Schaberg Reactive and Non-Proliferative ......May 16, 2020  · Reactive and Non-Proliferative Lesions Prepared by Kurt Schaberg Biopsy Site Changes Non-Proliferative

Prepared by Kurt Schaberg Reactive and Non-Proliferative ......May 16, 2020  · Reactive and Non-Proliferative Lesions Prepared by Kurt Schaberg Biopsy Site Changes Non-Proliferative

Bevacizumab in the treatment of ovarian cancer · 2017. 7. 14. · 4 bevacizumab for ovarian cancer kce report 285 8.1 unproven effectiveness of first-line bevacizumab on overall

Bevacizumab in the treatment of ovarian cancer · 2017. 7. 14. · 4 bevacizumab for ovarian cancer kce report 285 8.1 unproven effectiveness of first-line bevacizumab on overall

Diffuse Proliferative GN

Diffuse Proliferative GN

Prevalence of diabetic retinopathy in the Dubrovnik ...retinopathy present was graded as mild non-proliferative retinopathy, moderate-severe non proliferative retinopathy or proliferative

Prevalence of diabetic retinopathy in the Dubrovnik ...retinopathy present was graded as mild non-proliferative retinopathy, moderate-severe non proliferative retinopathy or proliferative

Pituitary Proliferative Rat

Pituitary Proliferative Rat

Ranibizumab for proliferative and non- proliferative diabetic ......Non-proliferative diabetic retinopathy (NPDR) occurs when there are only intraretinal microvascular changes, such

Ranibizumab for proliferative and non- proliferative diabetic ......Non-proliferative diabetic retinopathy (NPDR) occurs when there are only intraretinal microvascular changes, such

AVASTIN® (bevacizumab) Label

AVASTIN® (bevacizumab) Label

Maintenance Therapy for Advanced NSCLC · Bevacizumab pemetrexed cisplatin q3w Previously untreated stage IIIB/IV nonsquamous NSCLC Bevacizumab (7.5mg/kg) q3w Bevacizumab (7.5mg/kg)

Maintenance Therapy for Advanced NSCLC · Bevacizumab pemetrexed cisplatin q3w Previously untreated stage IIIB/IV nonsquamous NSCLC Bevacizumab (7.5mg/kg) q3w Bevacizumab (7.5mg/kg)

EFEKTIFITAS ANTI-VEGF BEVACIZUMAB SUBCONJUNGTIVA …

EFEKTIFITAS ANTI-VEGF BEVACIZUMAB SUBCONJUNGTIVA …

Mesangial proliferative GN

Mesangial proliferative GN